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A B S T R A C T
The marine microalga Tisochrysis lutea is an interesting source of nutrients and bioactive compounds such as
fucoxanthin and docosahexaenoic acid, used so far mainly in aquaculture. To investigate its dietary safety and
tolerability on mammals, male Sprague-Dowley rats were fed an AIN-76 diet containing 20% of T. lutea F&M-
M36 biomass, for 1 month.
T. lutea rich diet showed an apparent digestibility similar to that of the non enriched AIN-76 diet and did not
affect growth or animal behavior, but was associated to higher water intake, urinary excretion and urinary
sodium probably due to the high salt content of the algal biomass. However, blood pressure, creatinine and urea,
kidney morphology and heart left ventricular wall thickness were not affected. T. lutea fed rats showed an
increase in cholesterol high density lipoprotein, HDL (p < 0.05) and decreased plasma triglycerides (p=0.06),
together with an increased excretion of fecal lipids (p < 0.05). Up-regulation of PPARγ (p < 0.05) and UCP-1
(p < 0.05) and down-regulation of LPL genes (p < 0.05) in the liver of T. lutea fed rats were also observed.
These preliminary data indicate that the T. lutea-rich diet was well tolerated in the short term and suggest that
this marine microalga may represent a promising source of functional foods and bioactive compounds for the
control of dyslipidemias. Its salt content, however, poses a safety issue, which must be overcome before pro-
posing its use in humans.
1. Introduction
Tisochrysis lutea El M. Benif & I. Probert [1] is a marine microalga
belonging to the Haptophyceae, originally isolated from tropical sea-
water (Tahiti, French Polynesia). Although T. lutea is currently used
mainly in aquaculture, its high content of protein and fibers, together
with the presence of several bioactive compounds, makes it an inter-
esting source of nutraceutical and pharmaceutical products [2]. T. lutea
is in fact rich in polyunsaturated fatty acids (PUFA), mainly doc-
osahexaenoic acid (DHA, C22:6 ω3) [3,4], and carotenoids such as
fucoxanthin [5].
T. lutea is not commercially available for human consumption un-
like other microalgae such as Chlorella, Dunaliella, Arthrospira, Nostoc,
Aphanizomenon and Tetraselmis [6,7] and its safety need still to be
evaluated.
In a preliminary screening in human cells and in Artemia salina, we
recently observed that T. lutea F&M-M36 extracts exhibit an IC50 of
6 g/L, showing an intermediate degree of toxicity compared to the other
strains analyzed [6].
Nuno et al. (2013) observed no acute toxicity in rats fed I. galbana T-
ISO (=Tisochrysis lutea) up to 50mg/day. In the same study, the mi-
croalga administered at a dosage of 50mg/day for 8 weeks promoted
body weight loss in healthy rats and maintained the weight in those
with diabetes; neither significant histopathological alterations of the
gastrointestinal tract nor kidney function impairment were reported in
healthy rats, but diabetic rats exhibited some indication of superficial
intestinal chronic low-inflammation [9]. Herrero and coworkers (1993)
conducted a study administering I. galbana Parke, a microalga phylo-
genetically close and physiologically similar to T. lutea, to weaning rats
as the sole source of protein, corresponding to a 35% of algal biomass in
the diet, for four weeks [8]. Compared to a casein treated group, de-
creased weight gain and a higher intake of water were observed.
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Relative heart weight was also lower, but no haematological abnorm-
alities with the exception of increased blood urea, were reported. Be-
sides genetics, one of the main differences between I. galbana and T.
lutea is that I. galbana is rich in both eicosapentaenoic acid (EPA, C20:5
ω3) and DHA, while T. lutea only in DHA (Molina Grima et al., 1992;
Bendif et al., 2013; Ryckebosch et al., 2014; Tibaldi et al., 2015). These
few studies on rats were not intended to specifically address the dietary
safety and tolerability at high dosages. Therefore, we performed an
extensive study by testing the effects of a diet containing 20% T. lutea,
administered for 1month to healthy rats. This percentage corresponds
to 12 g of microalgal dry biomass/kg of body weight, translatable into a
daily intake of 159 g in a 70 kg human, by applying the human
equivalent dose (HED) calculation [10], thus, much above the expected
daily human consumption.
2. Material and methods
2.1. Biomass production, preparation and composition
T. lutea F&M-M36, from the Fotosintetica & Microbiologica S.r.l.
Culture Collection of Microalgae and Cyanobacteria, was cultivated in
GWP® photobioreactors [11] in a semi-batch mode. The total sodium
concentration in the medium (30 g/L salinity) was 0.37mol/L. The
biomass was harvested by a centrifugal separator (Westfalia mod.
SSD18, GEA Group Aktiengesellschaft, Düsseldorf, Germany), frozen,
lyophilized and powdered. Before lyophilization the dry biomass con-
tent in the concentrate was 12–15%. The powdered biomass was stored
at −20 °C until use. Total protein content was estimated as N × 6.25,
where N is the nitrogen content determined through elemental analysis
(CHNSO Analyzer, Thermoelectron Corp., USA). Carbohydrate content
was determined following Dubois et al. (1956) and lipid content fol-
lowing Marsh & Weinstein (1966) [12,13]. Humidity was analyzed
following ISTISAN protocols (ISTISAN Report 1996/34, Method B, Page
7). Fiber was determined according to AOAC Method 985.29. Fatty acid
composition was evaluated by using the standard method for food of
the Italian Ministry for Health (ISTISAN Report 1996/34, p. 47). Fatty
acids were extracted from lyophilized biomasses and methylated. The
methyl esters were analyzed with a GC–MS system (Abiusi et al., 2014).
Fatty acids were identified by comparing retention times with those of
authentic standards (Supelco® 37 Component FAME Mix, Italy). Sodium
was determined by atomic absorption spectrometry (Rupérez, 2002).
The content of salt was estimated from sodium concentration multiplied
by 2.5 (He et al., 2014). DNA and RNA were extracted from the freeze-
dried algal biomass by using TRIzol (Invitrogen, Carlsbad, CA, USA)
following manufacturer's instructions and quantified by using a Nano-
Photometer UV/Vis Spectrophotometer (Implen GmbH, München,
Germany).
2.2. Fucoxanthin determination
The fucoxanthin content of T. lutea F&M-M36 biomass and of the
abdominal fat in T. lutea F&M-M36 fed rats was studied. Sudan Red
(Sigma–Aldrich, Germany) (270 μL), the monitoring standard for
UV–Vis, and β-apo-carotenal (Sigma–Aldrich, Germany) (150 μL), the
internal standard for quantification, were added to T. lutea F&M-M36
freeze-dried biomass or to the fat (20mg). A methanol solution (7.5 mL)
was added and the solutions were heated at 60 °C for 15min. A diethyl
ether/petroleum ether solution (50:50, 7.5 mL) and a NaCl solution
(20% in water, 5 mL) were added and the solutions were carefully
stirred. The upper phase was collected in a rotary evaporator flask,
dried and then resuspended with a methanol/methyl tertiary butyl
ether (MTBE) 4:1 and butylated hydroxytoluene (BHT) (0.01%) solu-
tion (3mL). Chromatographic analysis of extracts from T. lutea F&M-
M36 biomass and from fat was carried out according to a modification
of the method by Kim et al. (2012). Fucoxanthin separation was
achieved with an HPLC (Hewlett Packard 1050, California, USA)
equipped with a C30 reverse phase column (YCM Carotenoid,
4.6 mm×250mm, 5 μm particle size) (Waters, Massachusetts, USA),
and a UV photodioide array detector (Hewlett Packard 1050,
California, USA). A gradient method with two eluents was used, eluent
A: 81% MTBE, 10% methanol, and 9% deionised water and eluent B:
93% MTBE and 7% methanol. The injection volume was 20 μL with a
constant flow rate of 1mL/min, at 25 °C temperature. The detection
was performed at 450 nm. The quantification was performed by in-
ternal standard calibration. Commercial fucoxanthin (Sigma-Aldrich,
Germany) standard solutions (20, 40, 60, 80, 100, 120 μgmL-1 in me-
thanol/MTBE 4:1), with β-apo-carotenal (50 μg/mL) and Sudan Red
(90 μg/mL) were prepared. The rate between the area under the peaks
of fucoxanthin standard solutions and the area under the internal
standard peak was plotted against fucoxanthin standard solution con-
centrations (μg/mL) to obtain a calibration curve adopted to quantify
the concentration of fucoxanthin in the microalgal biomass and in the
fat sample [5].
2.3. Diets preparation
The AIN-76 (American Institute of Nutrition, 1977) diet was pre-
pared from its components (Laboratorio Dottori Piccioni S.r.l., Milan,
Italy) and contained 5% fat (corn oil). In the microalga-rich diet, which
contained 20% lyophilized microalgal biomass, the different compo-
nents were adjusted so as to compensate for protein, lipid, carbohydrate
and fiber deriving from T. lutea F&M-M36 biomass and to maintain the
caloric intake of the diet (Table 1).
2.4. Animals and treatments
All procedures were carried out in agreement with the European
Union Regulations on the Care and Use of Laboratory Animals (OJ of
ECL 358/1, 12/18/1986), according to Italian regulations on the pro-
tection of animals used for experimental and other scientific purposes
(DM 116/1992), after approval from the Italian Ministry for Scientific
Research. We used 6- to 8-weeks male Sprague-Dowley rats (Nossan
S.r.l., Milan, Italy). The animals were housed in plastic cages with wire
tops and maintained at a temperature of 22 °C, with a 12:12-h light-
dark cycle. After their arrival from the supplier, animals were accli-
matized for a week, during which they were fed a standard lab chow.
Rats were then randomly allocated to two experimental groups: rats fed
AIN-76 diet (controls, n= 4) or a T. lutea F&M-M36 rich diet (n= 8),
ad libitum, for 1month.
Individual animal body weights were recorded weekly, starting
from the first day of experiment. During the third week of treatment,
the animals were placed in metabolic cages for one day in order to
collect 24-h urine and feces, to assess the apparent digestibility of the
diet and to measure water daily consumption. Samples of feed and fecal
samples were collected and weighed and oven-dried at 55 °C until
constant weight. After drying, the coefficient of apparent digestibility
Table 1
Composition of the experimental diets (g/100 g of diet).
AIN-76 diet T. lutea F&M-M36 rich diet
Lyophilized algal biomass – 20
Corn oil 5 2
Sucrose 50 50
Starch 15 11.8
Casein 20 11.5
Cellulose 5 1.4
Mineral Mix AIN 76 3.5 3.5
Vitamin Mix AIN 76 1 1
Coline 0.2 0.2
DL Methionine 0.3 0.3
Values in bold indicate constituents of the diet that were adjusted in order to
compensate for components deriving from algal biomass.
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was calculated as follows: Apparent digestibility %= [feed dry weight
– 24-h feces dry weight/feed dry weight]× 100.
Systolic, diastolic blood pressure, mean arterial pressure (MAP) and
frequency were monitored in conscious rats by noninvasive computer-
ized tail-cuff method (Visitech BP-2000 Series II Blood Pressure
Analysis System) at week 3 of treatment, after two days of training.
At the end of the study, rats were euthanized by inhalation of CO2.
External surface, all orifices and the cranial, thoracic, abdominal and
pelvic cavities, including viscera of all rats were examined. Brain, heart,
kidneys, liver, bladder, caecum, colon, spleen were collected, weighed
and stored for further analyses.
The thickness of the tibio-tarsal joint was also measured by using a
micrometer (screw-gauge) to assess the possible presence of peripheral
edemas. Blood was collected for clinical biochemistry (lipid profile,
kidney and liver function).
2.5. Blood and urine biochemistry
Plasma chemistry parameters were performed at Careggi Hospital,
Florence, Italy and included: urea, creatinine, alkaline phosphatase,
alanine aminotransferase (ALT), aspartate aminotransferase (AST),
total cholesterol, low density lipoprotein (LDL) and high density lipo-
protein (HDL). Urinary sodium and uric acid were also measured and
expressed relative to the 24 h urine.
2.6. Histological analysis
For histological evaluations, tissue samples (heart, kidney, liver,
urinary bladder and brain) were collected and fixed in phosphate buf-
fered 4% formalin for 12 h. Samples were dehydrated in ethanol and
embedded in paraffin. 5 μm tick sections were hematoxylin-eosin
stained and observed for morphological analysis. Regarding heart, the
thickness of the ventricular wall was also measured. In detail, five
microscopical fields per animal were registered by a digitizing camera
applied to a light microscope with a 20 x objective, each field corre-
sponding to a test area of 141,100 μm2. On digitized images, mea-
surements of ventricular wall thickness were carried out using ImageJ
1.33 image analysis software (http://rsb.info.nih.gov/ij) by two in-
dependent observers in blind fashion.
2.7. Fecal water and lipid content
Fresh fecal samples were harvested and frozen at −20 °C until
analyses. To determine the degree of diarrhea, fecal samples were dried
in a dehumidified oven at 50 °C until stable in weight and the water
content was expressed as percentage of the fresh fecal weight [14]. To
estimate lipid content, dried fecal samples (about 30mg) were re-sus-
pended in 500 μL of normal saline. Then, 500 μL of chloroform-me-
thanol (2:1; v/v) were added in order to extract the lipids, according to
http://www.bio-protocol.org/e1375.
2.8. RT-PCR
RNA was extracted from tissue homogenates by using a commer-
cially available kit following manufacture's instructions (Macherey-
Nagel, Bethlehem, USA). For first-strand cDNA synthesis, 1 μg of total
RNA from each sample was reverse-transcribed by using the RevertAid
RT Kit (Thermo Scientific, Waltham, MA USA). Primers were designed
on the basis of the rat GenBank sequences (Supplementary Table 1). For
each target gene, the relative amount of mRNA in the samples was
calculated as the ratio of each gene to β-actin mRNA [15].
2.9. Statistical analysis
Statistical analyses were conducted using GraphPad Prism 5.0
software (GraphPad, San Diego, CA). D'Agostino and Pearson omnibus
normality test was applied to verify the Gaussian distribution of each
variable. Differences on body weight gain, organs weight, clinical
chemistry parameters, fecal water and lipid content, blood pressure
measurements and on gene expression were analyzed using unpaired t-
test with Mann Whitney correction or t-test when appropriate. Results
are presented as means± SEM. Significance was assigned at p < 0.05.
3. Results and discussion
Thanks to their huge biodiversity, microalgae are a fascinating
source of biologically active compounds with potential application as
nutraceutical or pharmaceutical products [16]. In this context, the
marine microalga T. lutea F&M-M36 deserves particular attention as it
combines a relatively high content of proteins (42.4%) and fibers
(18.2%) and with a very good content of mono- (3.8%) and poly-
unsaturated (4.1%) fatty acids, including DHA (Table 2), and of the
carotenoid fucoxanthin (0.6%), whereas ash content was 13.1%.
To our knowledge, this is the first study addressing the safety and
tolerability of a T. lutea F&M-M36-rich diet in rats.
During the study period, no adverse effects regarding food con-
sumption, animal behavior or physical abnormalities were observed
with the alga-enriched diet. The growth curves and weight gain were
not statistically different from those of the controls by Mann-Whitney
test (Supplementary Fig. 1).
Given that this observation is limited to the 30 days feeding period,
we cannot exclude significant effects in the long term, as reported by
Nuno et al. (2013) and Herrero et al. (1993) [8,9].
The apparent digestibility of the T. lutea F&M-M36 rich diet was
slightly lower compared to the AIN-76 diet (− 4%) but the difference of
caecum weight was not significant between the two groups. However,
the amount of daily feces and the percentage of fecal water content
were significantly augmented (p < 0.05), suggesting that T. lutea F&M-
M36 may also exert positive effects on intestinal health, which deserves
to be better explored (Table 3). The T. lutea F&M-M36 rich diet contains
more NaCl compared to the AIN76 normal salt diet (1.5% vs 0.3%); this
is very likely the reason for the double water daily consumption
(Table 3), as also previously reported by Herrero et al. [9], triple urine
daily production (Table 3) and significantly increased 24 h urinary Na+
excretion compared to controls (5.7 ± 0.45 vs 0.48 ± 0.05mE in
24 h; p < 0.01).
A very high salt diet (8% of NaCl) causes left ventricular hyper-
trophy and elevates blood pressure [17]; in our experiment, we ob-
served an increased relative heart weight in rats fed T. lutea F&M-M36
(p < 0.05; (Supplementary Table 2) that was neither associated to an
increased left ventricular wall thickness, a sign of cardiac hypertrophy,
Table 2
Fatty acid composition of T. lutea F&M-M36 biomass (% of dry weight).
Fatty acids composition % of dry weight
SFA 7.10
MUFA 3.80
PUFA 4.14
22:6n-3 (DHA) 1.01
20:5n-3 (EPA) < 0.1
18:3n-3 (α-linolenic acid) 1.60
Total ω-3 2.61
18:2n-6c (linoleic acid) 1.13
18:3n-6 (γ-linolenic acid) 0.04
20:2n-6 (eicosadienoic acid) < 0.1
20:3n-6 (eicosatrienoic acid) 0.35
20:4n-6 (arachidonic acid) < 0.1
Total ω-6 1.17
18:1n-9c (oleic acid) 2.91
Total ω-9 2.91
ω-6/ω-3 0.45
SFA: Saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA:
Polyunsaturated fatty acids.
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nor to blood pressure variations (Table 4) or peripheral edemas. Crea-
tinine and urea levels, measured to assess renal function variations
(Table 4), and kidney histopathology were also normal. However, since
excessive salt contributes to cardiovascular risk, a reduction of NaCl
content of the algal biomass, for instance by modifying the composition
of the growth medium or by adopting a more efficient washing, is ne-
cessary before T. lutea F&M-M36 can be proposed in humans.
MAP=mean arterial pressure. Data are expressed as mean ± SEM;
*p < 0.05. (# data relative to AIN-76 control diet, were previously
published elsewhere, [19]).
Issues associated with the use of microalgae as a food source, also
include their nucleic acid content, which upon metabolism produce uric
acid leading to diseases such as gout and uric acid nephrolithiasis. The
content of DNA and RNA of the T. lutea F&M-M36 biomass was 0.1%
and 0.8%, respectively, resulting in an intake of 120mg/kg of nucleic
acids per day. By applying HED calculation [10] the daily dose in rats
translates into 1.5 g/day in a 70 kg human, below the safety limit of
4 g/day established by the World Health Organization [18]. Never-
theless, the 24 h urinary uric acid excretion, even if within the values
previously reported for control rats [17], was augmented in T. lutea F&
M-M36 group compared to controls (0.07 ± 0.01 vs 0.15 ± 0.01mg;
p < 0.01); moreover, in the kidney, in the proximal and distal con-
volute tubules of a single rat fed T. lutea F&M-M36, we observed the
presence of an amorphous and eosinophilic deposit (Supplementary
Fig. 2).
The kidneys of remaining animals did not show any morphological
damage but in the same animal, a huge crystal and amorphous deposit,
macroscopically similar to a little stone, rolling in the urinary bladder
was found. An analogous formation was described in our previous study
focused on an Arthrospira platensis Gomont-rich diet [19]. Although this
may be caused by retrograde seminal vesicles discharges, we cannot
exclude the deposition of an uric acid crystal [20]. Even if the dose of T.
lutea F&M-M36 in the 20% diet largely exceeds the expected human
consumption, these findings, although sporadic, should not be ignored
when proposing its use in humans.
Despite a reduced weight (p < 0.05) (Supplementary Table 2), the
liver showed a normal morphological structure in both experimental
groups. In hepatocytes, no cyto-pathological signs of steatosis, hemo-
siderin accumulation or biliary stasis were present (data not shown).
Serum aspartate transaminase (AST), alkaline phosphatase and alanine
aminotransferase (ALT) did not indicate any hepatic impairment
(Table 4).
Interestingly, although rats were all fed a well-balanced and iso-
caloric diet, we observed unexpected, positive effects on lipid meta-
bolism in animals fed the alga-enriched diet. Compared to the control
group, total cholesterol concentration was significantly higher, but this
effect was mainly ascribed to the augmented HDL (+112%) (p < 0.05)
since LDL levels did not change (Table 4). Rats fed T. lutea F&M-M36
showed also significantly higher fecal excretion of lipids (+75%)
(Table 2), suggestive of a decreased intestinal lipid absorption, which
resulted in reduced plasma triglycerides (−73%) (p= 0.06) (Table 4).
Reduced triglycerides levels were reported by Herrero and cow-
orkers (1993) in weaning rats fed I. galbana, but they did not investigate
the mechanism involved [8]. On the contrary, Nuno et al. (2013) re-
ported no effects on triglycerides using I. galbana T-ISO (T. lutea) as
supplement [9]. Various bioactive components in T. lutea F&M-M36,
including ω-3 fatty acids and fucoxanthin, might act synergistically to
alter plasma lipid profile and fecal fats concentration. ω-3 have long
been known to dose-dependently lower plasma triglycerides with the
minimal effective dose being>2 g/day [21]. In our study, we calcu-
lated that rats received about 30mg of DHA daily, corresponding to a
daily intake of 1.58 g in a 70 kg human. T. lutea biomass also contains
ω-6 (about 10.1% of total fatty acids) but the ratio ω-6/ω-3 in this
microalga strain is favorable (0.58) since a low ω-6/ω-3 ratio benefi-
cially modulates the lipid profile in rats [22]. A fucoxanthin-supple-
mented diet (0.2%) increased plasma HDL and fecal excretions of total
lipids, reducing total cholesterols and triglycerides in mice fed a high
fat diet [23]. T. lutea F&M-M36 biomass contains 0.6% (dry weight) of
the carotenoid fucoxanthin corresponding to 0.12% in the diet, but no
trace of fucoxanthin in the abdominal fat (despite being intensely or-
ange colored) of T. lutea F&M-M36 fed rats was detected maybe due to
its rapid biotransformation into fucoxanthinol and amarouciaxanthin A
or to a very low level of fucoxanthin accumulation in the adipose tissue
[24].
However, since we observed similar positive results on lipid profile
in rats fed an A. platensis (spirulina) rich diet, a microalga with different
fatty acid and carotenoid compositions [19], we cannot exclude that
other bioactive compounds may have a role. Some studies have in fact
suggested that dietary proteins with low ratios of methionine–glycine
and lysine–arginine, such as those from soy, compared to casein, exert
also hypocholesterolemic and hypotriglyceridemic effects in experi-
mental animals [25]. Both A. platensis biomass used in our previous
study [19] and I. galbana T-ISO (T. lutea) [26], have low ratios of me-
thionine–glycine (0.08 and 0.37 vs 0.97) and lysine–arginine (0.56 and
0.98 vs 2.4), compared to casein [27], the sole source of proteins in the
AIN-76 diet. It is worth considering that the beneficial effects on blood
lipids of the T. lutea F&M-M36 rich diet, were observed despite that
only about half of the total protein content was from the microalgal
biomass and the remaining from casein (Table 1).
To explore the possible molecular mechanisms involved in the
beneficial effects on lipid profiles, we analyzed the expression of PPAR-
α, PPAR-γ, HMGCR, APOA-1, UCP-1, LPL and APOCIII genes in the
liver. A hierarchical cluster analysis distinguished the different ex-
pression profiles of these genes in the liver of rats fed T. lutea F&M-M36
and in controls (Fig. 1).
Interestingly, we observed an increased expression of PPAR-γ and
UCP-1 and a reduced expression of LPL in the liver of T. lutea F&M-
Table 3
Effects of T. lutea F&M-M36-rich diet on water daily consumption, urine and feces production and on fecal water content.
Water daily consumption (ml) Urine daily production (ml) Feces daily production (g) Water fecal content (%) Fecal lipids excretion (%)
AIN-76 diet # n=4 21.5 ± 1.7 7.0 ± 1.3 1.8 ± 0.4 50.4 ± 8.9 13.7 ± 2.5
T. lutea F&M-M36 diet= 8 42.0 ± 1.9 ** 21.6 ± 1.1 ** 3.8 ± 0.4 * 64.5 ± 1.1* 24.7 ± 3.5
Data are expressed as mean ± SEM.*p < 0.05; ** p < 0.01. (# data relative to AIN-76 control diet, were previously published elsewhere, [19]).
Table 4
Effect of T. lutea F&M-M36-rich diet on biochemical and blood pressure para-
meters.
AIN-76 diet #
n=4
T. lutea F&M-M36 diet n= 8
Urea g/L 0.4 ± 0.0 0.3 ± 0.0
Creatinine mg/dL 0.3 ± 0.1 0.3 ± 0.0
AST U/L 290.5 ± 176.5 180.0 ± 67.5
ALT U/L 75.0 ± 16.1 59.2 ± 4.5
Alkaline phosphatase U/L 155.0 ± 28.0 173.7 ± 12.9
Triglycerides mg/dL 187.062.0 52.3 ± 5.2 (p= 0.06)
Total cholesterol mg/dL 73.0 ± 4.0 131.5 ± 6.2*
HDL mg/dL 55.0 ± 5.3 117.9 ± 5.8*
LDL mg/dL 5.0 ± 0.0 7.0 ± 1.3
Systolic 142.9 ± 5.3 130.2 ± 7.6
Diastolic 81.1 ± 7.1 66.8 ± 14.4
Pulse 386.1 ± 32.3 351.3 ± 27.2
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M36-fed animals compared to controls (p < 0.05) (Table 5).
Although PPAR-γ is expressed at a much lower level in the liver than
in adipose tissue, PPAR-γ dependent effects in the liver have been re-
ported. The brown alga wakame (Undaria pinnatifida), also containing
fucoxanthin, increased PPARγ expression in the liver and ameliorated
lipid profiles in a murine model of diet-induced obesity [28], aug-
menting also the expression of UCP-1 gene, usually expressed only in
adipose tissue [29]. The very low levels of plasma triglycerides ob-
served in T. lutea F&M-M36 fed rats could be associated also to the
unexpected increased expression of UCP-1 in the liver. The ectopic up-
regulation of UCP-1, in fact, decreased body weight and reduced fat in
the liver and adipose tissues in high fat diet-induced dyslipidemia [30].
LPL is a gene target of PPAR-γ signaling and its liver-specific over-
expression increased liver triglyceride content and insulin resistance in
mice [31]. These effects are of interest since PPARγ agonist, such as
thiazolidinediones, improve dyslipidaemia but are not devoid of side
effects.
4. Conclusions
Overall, our results show that a balanced diet, supplemented with
20% T. lutea F&M-M36 biomass is well tolerated over 30 days and does
not elicit significant negative effects in rats, but the relatively high salt
content of the biomass represents a safety concern to be addressed
before being used as food; nucleic acid content may also limit the
amount of algal biomass that can be included in the diet. Indeed, we
observed that T-ISO biomass added 5% in the diet did not increase
water consumption or diuresis and did not affect uric acid excretion in a
long-term experiment in rodents (manuscript in preparation). Despite
the small number of animals used in the present study that may limit
the significance of our results, we observed that lipid metabolism was
significantly and positively affected by T. lutea F&M-M36-based diet.
These preliminary effects on lipid homeostasis and on PPAR-γ signaling
deserve to be better explored in a model of metabolic syndrome or
dyslipidemia where the biological relevance of these findings could be
highlighted.
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